The activity of nintedanib in an animal model of allogenic left lung transplantation resembling aspects of allograft rejection
Autor: | Christof Schmid, Elke Boxhammer, Karla Lehle, Lutz Wollin, Stephan Hirt, Marietta von Suesskind-Schwendi, Stephan Schreml |
---|---|
Rok vydání: | 2017 |
Předmět: |
Graft Rejection
Vascular Endothelial Growth Factor A Pulmonary and Respiratory Medicine medicine.medical_specialty Indoles medicine.medical_treatment Clinical Biochemistry Rats Inbred WKY Gastroenterology Organ transplantation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Animals Lung transplantation Lung Molecular Biology Platelet-Derived Growth Factor Bronchus biology business.industry Allografts Rats Inbred F344 Rats Surgery Transplantation Vascular endothelial growth factor Disease Models Animal medicine.anatomical_structure 030228 respiratory system chemistry 030220 oncology & carcinogenesis biology.protein Nintedanib business Immunosuppressive Agents Platelet-derived growth factor receptor Lung Transplantation |
Zdroj: | Experimental Lung Research. 43:259-270 |
ISSN: | 1521-0499 0190-2148 |
Popis: | Aim of the Study: The prevention and treatment of chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx) remain unsatisfactory. Growth factors may play an important role in the development of CLAD. This study evaluated the effects of nintedanib, a receptor tyrosine kinase inhibitor, in the treatment of CLAD after experimental LTx. Materials and Methods: A rat model of left lung allo-transplantation (Fisher 344 to Wistar Kyoto) was used to evaluate the effect of nintedanib (50 mg/kg per day) on the development of CLAD. Therapy with nintedanib began 2 days before LTx and ended on postoperative day (POD) 20 (n = 6) or 60 (n = 6). Nontreated animals who underwent LTx (n = 12) were used as controls, whereas naive lungs (n = 24) served as reference for physiological healthy organs without transplantation damage or medical effects. Acute and chronic rejection were evaluated on POD 20 and 60, respectively. Results: Immunohistologic analysis showed a decrease in growth factors/receptors on POD 60 (nintedanib-treated vs. nontreated controls: platelet-derived growth factor (PDGF) A: [P |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |